Nothing Special   »   [go: up one dir, main page]

BR0310099A - método para tratar dislipidemia ou uma doença associada com a dislipidemia - Google Patents

método para tratar dislipidemia ou uma doença associada com a dislipidemia

Info

Publication number
BR0310099A
BR0310099A BRPI0310099-5A BR0310099A BR0310099A BR 0310099 A BR0310099 A BR 0310099A BR 0310099 A BR0310099 A BR 0310099A BR 0310099 A BR0310099 A BR 0310099A
Authority
BR
Brazil
Prior art keywords
dyslipidemia
treating
disease associated
apolipoprotein
effect
Prior art date
Application number
BRPI0310099-5A
Other languages
English (en)
Inventor
Jean-Louis H Dasseux
Anna A Shenderova
Thomas J Rea
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of BR0310099A publication Critical patent/BR0310099A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO PARA TRATAR DISLIPIDEMIA OU UMA DOENçA ASSOCIADA COM A DISLIPIDEMIA". A invenção fornece métodos de tratar ou prevenir uma condição ou distúrbio associados com a dislipidemia com composições que compreendem complexos de apolipoproteína-esfingomielina. Os métodos da invenção permitem a redução, em 4 a 20 vezes, da quantidade de apolipoproteína requerida para a administração terapêutica para efetuar um efeito melhorativo.
BRPI0310099-5A 2002-05-17 2003-05-16 método para tratar dislipidemia ou uma doença associada com a dislipidemia BR0310099A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38151202P 2002-05-17 2002-05-17
PCT/US2003/015467 WO2003096983A2 (en) 2002-05-17 2003-05-16 Method of treating dyslipidemic disorders

Publications (1)

Publication Number Publication Date
BR0310099A true BR0310099A (pt) 2007-03-20

Family

ID=29550136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0310099-5A BR0310099A (pt) 2002-05-17 2003-05-16 método para tratar dislipidemia ou uma doença associada com a dislipidemia

Country Status (8)

Country Link
US (2) US20040067873A1 (pt)
EP (1) EP1511508A4 (pt)
JP (1) JP2006507223A (pt)
AU (1) AU2003239489A1 (pt)
BR (1) BR0310099A (pt)
CA (1) CA2486127C (pt)
MX (1) MXPA04011312A (pt)
WO (1) WO2003096983A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064820A2 (en) * 2003-01-20 2004-08-05 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
JP5154218B2 (ja) * 2004-03-16 2013-02-27 ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法
EP1576894A1 (en) * 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
ATE539741T1 (de) 2004-11-30 2012-01-15 Tno Sphingolipide bei der behandlung und prävention von hepatischer steatose
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
CA2653840A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
CA2654661C (en) * 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
NZ594516A (en) * 2009-02-16 2012-12-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
WO2010131718A1 (ja) * 2009-05-13 2010-11-18 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
MX2012014928A (es) 2010-06-30 2013-03-22 Csl Ltd Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma.
CA2807448A1 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
EP2767546B1 (en) 2011-02-07 2018-10-17 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses therof
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用
BR112014014403A2 (pt) * 2011-12-21 2017-06-13 Csl Ltd regime de dosagem para formulações de apolipoproteína
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
US20160074473A1 (en) 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10532105B2 (en) 2015-07-10 2020-01-14 Peptinovo Biopharma, LLC. Formulations for improving the efficacy of hydrophobic drugs
KR20240044543A (ko) 2016-11-10 2024-04-04 시에스엘 리미티드 심근경색의 재구성된 고밀도 지질단백질 치료
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
CA3177243A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
IL307670A (en) 2021-04-15 2023-12-01 Abionyx Pharma Sa Use of lipid-binding protein-based complexes in organ preservation solutions
WO2023196804A1 (en) * 2022-04-04 2023-10-12 Phyto Tech Corp. Use of apolipoprotein a-v as an oral ingestible protein for nutraceutical or pharmaceutical applications
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1993025581A1 (en) 1992-06-12 1993-12-23 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
US6258596B1 (en) * 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
AU710061B2 (en) 1996-03-29 1999-09-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6267377B1 (en) * 1999-11-12 2001-07-31 Herman W. Griggs Astronomy-based card game
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
AU2002214644A1 (en) 2000-10-13 2002-04-22 University Of Cincinnati Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
CN1668645A (zh) 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Also Published As

Publication number Publication date
EP1511508A2 (en) 2005-03-09
US7994120B2 (en) 2011-08-09
MXPA04011312A (es) 2005-02-14
JP2006507223A (ja) 2006-03-02
US20040067873A1 (en) 2004-04-08
CA2486127A1 (en) 2003-11-27
EP1511508A4 (en) 2009-07-08
WO2003096983A2 (en) 2003-11-27
US20080269111A1 (en) 2008-10-30
AU2003239489A1 (en) 2003-12-02
CA2486127C (en) 2014-03-11
AU2003239489A8 (en) 2003-12-02
WO2003096983A3 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
NO20060871L (no) Azepinderivater som farmasoytiske midler
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
UY26130A1 (es) Compuestos para tratar la obesidad
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR0008687A (pt) Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]